Replimune Group, Inc. (REPL) Deep Dive Video

Replimune is a high-stakes regulatory binary: RP1 approval could validate a differentiated oncolytic immunotherapy platform, unlock financing, and drive major upside, while another FDA rejection could push the company toward severe dilution or asset liquidation.